LICENSE AGREEMENT by and between PFIZER INC. and REPLIGEN CORPORATION DECEMBER 28, 2012License Agreement • March 15th, 2013 • Repligen Corp • Biological products, (no disgnostic substances) • New York
This License Agreement (the “Agreement”) is entered into as of December 28, 2012 (the “Effective Date”), by and between Pfizer Inc., a corporation organized and existing under the laws of Delaware and having a principal place of business at 235 East 42nd Street, New York, NY 10017 (“Pfizer”) and Repligen Corporation, a corporation organized and existing under the laws of Delaware and having its principal place of business at 41 Seyon St, Waltham, MA 02453 (“Company”). Pfizer and Company may each be referred to herein individually as a “Party” and collectively as the “Parties.”
